

Mitochondrial dysfunction and lipotoxicity.

Citation for published version (APA):

Schrauwen, P., Schrauwen-Hinderling, V. B., Hoeks, J., & Hesselink, M. K. (2010). Mitochondrial dysfunction and lipotoxicity. *Biochimica et Biophysica Acta-Molecular and Cell Biology of Lipids*, 1801(3), 266-271. <https://doi.org/10.1016/j.bbalip.2009.09.011>

Document status and date:

Published: 01/03/2010

DOI:

[10.1016/j.bbalip.2009.09.011](https://doi.org/10.1016/j.bbalip.2009.09.011)

Document Version:

Publisher's PDF, also known as Version of record

Document license:

Taverne

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:


www.umlib.nl/taverne-license

Take down policy

If you believe that this document breaches copyright please contact us at:

repository@maastrichtuniversity.nl

providing details and we will investigate your claim.



Review

Mitochondrial dysfunction and lipotoxicity

Patrick Schrauwen^{a,*}, Vera Schrauwen-Hinderling^c, Joris Hoeks^a, Matthijs K.C. Hesselink^b^a Maastricht University Medical Centre (MUMC), Nutrition and Toxicology Research Institute Maastricht (NUTRIM), Department of Human Biology, P.O. Box 616, 6200 MD Maastricht, The Netherlands^b Human movement Sciences, Maastricht University Medical Centre, Maastricht, The Netherlands^c Radiology, Maastricht University Medical Centre, Maastricht, The Netherlands

ARTICLE INFO

Article history:

Received 27 May 2009

Received in revised form 28 August 2009

Accepted 13 September 2009

Available online 24 September 2009

Keywords:

Lipotoxicity

Mitochondria

Type 2 diabetes

Muscle

Fatty acid

ABSTRACT

Mitochondrial dysfunction in skeletal muscle has been suggested to underlie the development of insulin resistance and type 2 diabetes mellitus. Reduced mitochondrial capacity will contribute to the accumulation of lipid intermediates, desensitizing insulin signaling and leading to insulin resistance. Why mitochondrial function is reduced in the (pre-)diabetic state is, however, so far unknown. Although it is tempting to suggest that skeletal muscle insulin resistance may result from an inherited or acquired reduction in mitochondrial function in the pre-diabetic state, it cannot be excluded that mitochondrial dysfunction may in fact be the consequence of the insulin-resistant/diabetic state. Lipotoxicity, the deleterious effects of accumulating fatty acids in skeletal muscle cells, may lie at the basis of mitochondrial dysfunction: next to producing energy, mitochondria are also the major source of reactive oxygen species (ROS). Fatty acids accumulating in the vicinity of mitochondria are vulnerable to ROS-induced lipid peroxidation. Subsequently, these lipid peroxides could have lipotoxic effects on mtDNA, RNA and proteins of the mitochondrial machinery, leading to mitochondrial dysfunction. Indeed, increased lipid peroxidation has been reported in insulin resistant skeletal muscle and the mitochondrial uncoupling protein-3, which has been suggested to prevent lipid-induced mitochondrial damage, is reduced in subjects with an impaired glucose tolerance and in type 2 diabetic patients. These findings support the hypothesis that fat accumulation in skeletal muscle may precede the reduction in mitochondrial function that is observed in type 2 diabetes mellitus.

© 2009 Elsevier B.V. All rights reserved.

1. Introduction

The prevalence of type 2 diabetes mellitus is increasing dramatically and reaches epidemic proportions worldwide. The WHO predicts that 350–400 million people will suffer from type 2 diabetes in the year 2030 [1]. The increase in the prevalence of type 2 diabetes mellitus is a reflection of the alarming (and still increasing) number of people that are overweight. Environmental factors like consumption of high-fat and/or energy-rich diets and low levels of physical activity are likely to underlie this high prevalence of obesity.

In obesity, the accumulation of excessive fat in non-adipose tissues such as liver, heart and muscle (=ectopic fat accumulation) negatively impacts health. In sedentary humans, fat accumulation in skeletal muscle (and liver) strongly associates with insulin resistance, predisposing to the development of type 2 diabetes mellitus [2]. Indeed, both type 2 diabetic patients [3] and their diabetes-prone first-degree relatives [4,5] are characterized by high levels of intramyocellular lipids (IMCL) and muscular insulin resistance. On the contrary, endurance-trained athletes, who are among the most

insulin-sensitive subjects, are also characterized by high IMCL levels [3,6], indicating that high IMCL levels *per se* do not necessarily lead to insulin resistance. We (and others) have previously suggested that the increase in IMCL following endurance training serves to match the training-induced increase in oxidative capacity and reliance on fat as a substrate during exercise [6]. In contrast, the increase in IMCL under obesogenic/diabetogenic conditions is due to a surplus of fat availability (high plasma FFA levels, high-fat diets) and is NOT matched by improved oxidative capacity. Under the latter conditions the intermediates of IMCL metabolism such as fatty acyl-CoA, diacylglycerol and ceramides will also accumulate and especially these intermediates impede cellular insulin signalling (for review see: [7,8]). The above concept predicts that a low oxidative capacity—combined with high IMCL levels—predisposes to the development of insulin resistance. Indeed, (pre-)diabetic subjects are characterized by low oxidative capacity. In fact, in the recent 5–7 years, skeletal muscle mitochondrial dysfunction has been implicated in the aetiology of insulin resistance and type 2 diabetes mellitus.

2. Mitochondrial dysfunction and type 2 diabetes

In 2002, Kelley et al. [9] were one of the first to raise the issue of mitochondrial dysfunction in type 2 diabetes mellitus. Thus, the

* Corresponding author. Tel.: +31 43 3881502; fax: +31 43 3670976.
E-mail address: p.schrauwen@hb.unimaas.nl (P. Schrauwen).

authors observed that mitochondrial morphology was altered in type 2 diabetic patients, including a reduction in mitochondrial area size and an elevated number of damaged mitochondria. Mitochondrial surface area was found to correlate positively with insulin stimulated glucose disposal [9]. In addition, they reported that the activity of rotenone sensitive NADH:O₂ oxidoreductase, reflecting the overall activity of the respiratory chain, and citrate synthase were reduced in type 2 diabetic patients [9]. One year later, the interest for mitochondrial aberrations in the development of type 2 diabetes mellitus exploded when two independent studies were simultaneously published in different high-impact journals. These studies showed a coordinated reduction in the expression of genes encoding key enzymes in oxidative mitochondrial metabolism in (first-degree relatives of) diabetic patients [10,11]. Using micro-arrays it was shown that the mRNA expression of genes that encode for proteins involved in mitochondrial metabolism were mildly, but consistently lower expressed in muscle of type 2 diabetic patients and/or first-degree relatives of type 2 diabetic patients. Many of these genes are under the control of the transcription co-activator PGC1 α , which was also found to be reduced in type 2 diabetic patients [10,11] and in family history-positive non-diabetic subjects [10]. This reduction in PGC1 α gene expression has been confirmed by others [12,13]. However, it should be noted that changes in PGC1 α mRNA expression should be interpreted with caution, as PGC1 α has been shown to be regulated by post-translational modification and thus mRNA levels do not necessarily reflect activity of the protein [14].

Following these indications for aberrations in mitochondrial function in the diabetic state, several authors have applied non-invasive magnetic resonance spectroscopy (MRS) for the *in vivo* determination of skeletal muscle mitochondrial function. One way in doing so is by determining the rate of unidirectional flux through ATP synthase (ATP synthetic flux, fATPase) in the non-exercising state. This can be done by using the magnetization (saturation) transfer method in which the signal derived from ATP is temporarily suppressed and subsequent changes in the steady state MR signal of free phosphate are quantified to calculate unidirectional ATP synthesis rate. Simultaneously, flux through the tricarboxylic acid (TCA or Krebs) cycle can be determined non-invasively by carbon-13 (¹³C) MRS. Using this ¹³C- and ³¹P-MRS method, Petersen et al. [15] reported that muscular fATPase and oxidative metabolism (TCA cycle flux) were decreased by ~40% in elderly subjects when compared to BMI-matched young, healthy subjects without a family history of type 2 diabetes subjects. The older volunteers were also characterized by elevated levels of muscular fat and by muscular insulin resistance, suggesting that an age-associated decline in mitochondrial function might contribute to the development of insulin resistance. Using similar methodology, the same research group later found that IMCL and fATPase were, respectively, 80% higher and 30% lower in lean, but insulin-resistant offspring of type 2 diabetic patients who were matched for age, BMI and habitual physical activity with insulin sensitive healthy subjects [16]. Consistent with this finding, Szentroedi et al. [17] recently reported that *in vivo* ATP synthesis rate was decreased by 27% in non-obese metabolically well-controlled type 2 diabetic patients compared to young, healthy control subjects.

We have applied an alternative ³¹P-MRS method to investigate *in vivo* mitochondrial function by measuring the kinetics of phosphocreatine (PCr) resynthesis during recovery from submaximal exercise [18,19]. Importantly, and in contrast to the magnetization saturation transfer method, the PCR-recovery methodology assesses mitochondrial function under conditions of increased metabolic demand. When we then compared *in vivo* mitochondrial function in type 2 diabetic patients versus normoglycemic, obese control subjects matched for BMI [20], we showed that *in vivo* mitochondrial function was compromised by ~45% in type 2 diabetic patients [20]. Interestingly however, IMCL content was similar between the groups, suggesting that impaired mitochondrial function may be a more important

determinant of diabetes than IMCL levels *per se*. Recently, we have confirmed this observation of reduced *in vivo* mitochondrial function in type 2 diabetic patients and in addition showed that also first-degree relatives of type 2 diabetic patients (FDR) had a similar reduction in mitochondrial function [21]. Again, in these subjects that were all matched for BMI, no differences in IMCL content were observed between healthy obese, FDR and type 2 diabetic subjects [21]. Taken together, these studies are consistent in showing a reduction in *in vivo* mitochondrial function in insulin resistant subjects and/or type 2 diabetic patients.

In vivo mitochondrial function is not only determined by intrinsic mitochondrial function, but also by mitochondrial content and even substrate supply to the skeletal muscle. To address if the mitochondria *per se* have a reduced capacity, *ex vivo* studies are needed. Three studies have been published that examined *ex vivo* mitochondrial function (to determine “intrinsic mitochondrial function”) using high-resolution respirometry in muscle of type 2 diabetic patients. Boushel et al. [22] found that ADP-stimulated state 3 respiration, both with substrates for complex I and/or complex II, was normal in permeabilized skinned muscle fibers from type 2 diabetic patients, when corrected for mitochondrial density. In contrast, Mogensen et al. [23] reported that maximal ADP-stimulated respiration (state 3) with pyruvate as a substrate and respiration through the electron transport chain (ETC) was reduced in mitochondria isolated from diabetic patients. However, both studies did not determine *in vivo* mitochondrial function. In our study outlined above, in which we showed reduced *in vivo* mitochondrial function in type 2 diabetic patients and first-degree relatives [21], we also determined *ex vivo* mitochondrial function. We showed that a lower *ex vivo* (ADP-stimulated and maximally uncoupled) mitochondrial respiration underlies the reduction in *in vivo* mitochondrial function. Interestingly, we found similar tendencies of reduced intrinsic mitochondrial function in first-degree relatives of type 2 diabetic patients. These findings were not explained by reduced mitochondrial density, as both CS and mtDNA copy number were similar in all groups [21].

Taken together, there is indeed evidence for abnormalities in *in vivo* and intrinsic mitochondrial function in the (pre-)diabetic state. This led others to formulate the hypothesis that this (acquired or inherited) reduced mitochondrial function in the pre-diabetic state leads to accumulation of fat in muscle, thereby contributing to the development of insulin resistance [15,16].

3. Mitochondrial lipotoxicity

Although the above-mentioned hypothesis sounds firm, there are also data suggesting that mitochondrial dysfunction is not required for the development of type 2 diabetes mellitus or even the accumulation of muscular fat. First of all, several studies with genetically manipulated mouse models have suggested that a reduction in mitochondrial oxidative capacity in fact improves insulin sensitivity. Thus, Pospisilik et al. [24] generated mice with a deletion of the mitochondrial flavoprotein apoptosis-inducing factor (AIF) resulting in dysfunction of the oxidative phosphorylation. In contrast to what was expected, these mice had improved glucose tolerance and were protected from high-fat diet induced insulin resistance. Similarly, Wredenberg et al. [25] reported that mice with a skeletal muscle-specific deletion of mitochondrial transcription factor A (Tfam), resulting in marked reduction in oxidative phosphorylation capacity, were normal insulin sensitive and had an increased peripheral glucose uptake upon a glucose tolerance test. Also, PPAR α ablation in muscle—thereby decreasing fat oxidative capacity—resulted in improvements in glucose homeostasis, whereas PPAR α overexpression—improving oxidative capacity—had the opposite effects [26]. Together, these studies in genetically modified animals have suggested that in fact an ablation of mitochondrial oxidative capacity improves instead of impairs glucose homeostasis. Although

these studies could be interpreted as evidence against a causal role for mitochondrial dysfunction in the development of muscular insulin resistance, such an interpretation would be an oversimplification. It has been known for decades that in muscle (and other tissues) substrate competition between glucose and fatty acids determines the ultimate mix of fuel used for ATP production, as for example elegantly postulated in the Randle hypothesis [27]. A forced reduction/induction of the capacity to burn one substrate, will lead to a compensatory increase in the other substrate. The results of the above-mentioned mouse models can be explained by such substrate competition, as was also discussed by Finck et al. [26]. In fact, blockers of fat oxidation have previously been used for the treatment of type 2 diabetes. For example, we have previously shown that etomoxir, which reduces fat oxidation via inhibition of CPT1, indeed results in a reduction in fat oxidation but also an improvement in glucose metabolism, including enhanced basal GLUT4 translocation and lowering of plasma glucose levels [28]. In addition, part of the results in the animal studies is most likely explained by activation of the enzyme AMPK, a sensor of the energy status of the cell. Most likely, ablation of components of the oxidative phosphorylation system resulting in reduced mitochondrial function, will activate AMPK and thereby improve GLUT4 translocation and glucose uptake. For these reasons, the value of studies genetically disturbing oxidative phosphorylation for understanding the role of mitochondrial dysfunction in the development of type 2 diabetes mellitus is limited and interpretation of these studies should be done with more caution.

However, next to these mice studies, other observations have been reported that question the hypothesis that mitochondrial dysfunction underlies the development of type 2 diabetes mellitus or muscular fat accumulation. Thus, the acute elevation of circulating plasma fatty acids results in marked muscular fat accumulation and insulin resistance [29]—and importantly, these effects can also be induced in healthy or even endurance trained subjects, indicating independence of mitochondrial dysfunction. Furthermore, short-term consumption of high-fat diets (7 days) increased IMCL levels by 50% in lean, young and healthy subjects [30], whereas it has been shown that human subjects are capable of adjusting their fat oxidation to high-fat intake within this time-frame [31]. Moreover, it is important to realize that the suggestion that mitochondrial dysfunction precedes the development of insulin resistance originates from cross-sectional human studies in which a reduced mitochondrial function was always accompanied by increased/high muscular lipid content. For example, in offspring of type 2 diabetic patients a 30% reduction in mitochondrial function was already accompanied by a ~80% increase in IMCL content [16]. In our study, IMCL levels were comparable between diabetic patients, FDR and controls [21], despite marked differences in mitochondrial function. Finally, as recently addressed by Holloszy [32] it can be questioned if a 20–40% reduction in *in vivo* mitochondrial function or mitochondrial content as has been reported, would affect substrate oxidation and thereby fat accumulation in the resting state, given that mitochondria work at a very low fraction of their maximal capacity at rest.

Therefore, the question “cause or consequence” remains unanswered, and it is equally well possible that mitochondrial dysfunction in these studies is in fact the consequence of high concentrations of fat in the muscle cells: mitochondrial lipotoxicity (Fig. 1). Recent studies support this view: In a study where Szendroedi et al. [17] reported a 27% decrease in basal ATP synthesis rates in type 2 diabetic patients, they also found that plasma FFA levels correlated negatively with mitochondrial function, suggesting that lipid oversupply to the muscle may deteriorate mitochondrial function. Furthermore, the reduced PGC1 α gene expression that has been reported in insulin resistant subjects might also be the consequence of elevated plasma and/or muscular fatty acid levels. Thus, we and others recently showed that the acute elevation of plasma fatty acids, leading to accumulation of intramuscular lipids, was accompanied by down-




Fig. 1. Simplified schematic presentation of the “lipotoxicity hypothesis.” In diabetogenic conditions (obesity, high-fat diets, low physical activity), fatty acids will accumulate in muscle cells in the vicinity of mitochondria. These fatty acids can exert lipotoxic effects on mitochondrial function, thereby further aggregating oxidative capacity and muscle fat accumulation.

regulation of the transcriptional co-activator PGC1 α , as well as other genes involved in mitochondrial metabolism [33,34]. Also, the observed aberrations in mitochondrial morphology, i.e. smaller but most of all damaged mitochondria that were reported in type 2 diabetic patients [9] fit with the concept of lipotoxicity in skeletal muscle leading to mitochondrial dysfunction.

4. High-fat diet induced mitochondrial dysfunction

Several studies have tested the concept that in fact muscular fat accumulation may precede the development of mitochondrial dysfunction. Most of these studies have used high-fat diets to manipulate the IMCL content and assess the impact on mitochondrial function. Sparks et al. [35] were the first to show that feeding C57Bl/6J mice a high-fat diet for 3 weeks resulted in the down regulation of genes involved in mitochondrial oxidative phosphorylation [35]. In addition, these authors showed that in humans consumption of a high-fat diet (50 En% fat) for 3 days resulted in down regulation of PGC1 α and its target genes involved in oxidative phosphorylation as compared to an isocaloric normal fat diet (37 En% fat) [35]. In contrast, Turner et al. [36] reported that consumption of a high-fat diet for 5–20 weeks in C57Bl/6J mice induced insulin resistance despite an improved mitochondrial oxidative capacity. Similarly, we found that an 8-week high-fat dietary intervention in rats did not reduce *ex vivo* mitochondrial function, as assessed by high-resolution respirometry in isolated mitochondria. Moreover, the high-fat diet increased the protein content of PGC1 α [37], and the increase in PGC1 α protein content correlated with the protein content of several proteins of the OXPHOS system, suggesting that in fact mitochondrial density was increased after high-fat feeding. These improvements in mitochondrial metabolism were accompanied by marked accumulation of fat in skeletal muscle [37]. In concordance, Hancock et al. [38] showed that high-fat diets for 4–5 weeks increased mitochondrial density via a stimulatory effect of fatty acid levels on PPAR δ and PGC1 α protein content. Together, these data tend to suggest that high-fat diets—although leading to insulin resistance in rodents—are not accompanied by mitochondrial dysfunction. Rather they lead to improved mitochondrial oxidative capacity, arguing against a role for lipotoxicity in the development of diabetes-related mitochondrial dysfunction. However, the matter may be more complicated than can initially be deduced from these data. For example, two

studies have examined the time-course of changes in mitochondrial function upon high-fat diets. Thus, Chansemaume et al. [39] fed rats high-fat diets for 0, 3, 6, 9, 14, 20, or 40 days and determined *ex vivo* mitochondrial activity in permeabilized muscle fibers. They showed a transiently enhanced activity of the oxidative phosphorylation after 14 days, but a significant decrease at day 40. Similarly, Laurent et al. [40] showed in rats—using non-invasive imaging—that ATP synthesis rates decreased by 50% within 24 h of raising the fat content in the diet, but ATP synthesis returned to normal values after 2–3 weeks on the HF diet. However, prolonged high-fat feeding for longer than one month resulted in consistently lower ATP synthesis rates by 30–50% accompanied by steadily augmenting IMCL levels [40]. In ZDF rats, we recently showed that *in vivo* mitochondrial function (determined using non-invasive magnetic resonance spectroscopy) declines similarly with age (from 6 to 18 weeks of age) in diabetic ZDF rats and insulin-sensitive fa/+rats [41]. However, examination of intrinsic mitochondrial function—ADP-stimulated and maximally uncoupled respiration in isolated mitochondria—revealed that mitochondrial oxidative capacity also gradually decreased with age in the insulin-sensitive fa/+rats. In contrast, however, mitochondrial respiration initially improved in ZDF rats (from week 6 to week 12), when IMCL accumulates and type 2 diabetes develops, but subsequently showed a very rapid decline at an age of 18 weeks when overt diabetes develops (Lenears et al., Obesity, in press). Finally, Bonnard et al. [42] showed that 1 month of high-fat, high-sucrose diet feeding was sufficient to induce glucose intolerance in mice, without any evidence of mitochondrial dysfunction. However, when the diet intervention was extended up to 16 weeks, they observed altered mitochondrial biogenesis, structure, and function in mouse muscle tissue, accompanied by the induction of a diabetic state [42]. Interestingly, they showed that ROS production in skeletal muscle of diet-induced diabetic mice was increased after 16 weeks of high-fat diet, but not after 4 weeks. Finally, in muscle cells, they showed that glucose- or lipid-induced ROS production resulted in mitochondrial alterations *in vitro*, and these effects were blocked by antioxidant treatment. Interestingly, recent reports have provided strong experimental evidence for ROS production in the development of insulin resistance [43,44], suggesting that ROS production may link muscular fat accumulation, mitochondrial dysfunction and insulin resistance.

Taken together, these studies are overall consistent in showing that: (1) rodents have the capacity to (initially) adapt mitochondrial function to a high fat intake, (2) mitochondrial dysfunction only occurs when high-fat diets are continued for a longer period and (3) muscular fat accumulation and insulin resistance develop before mitochondrial function deteriorates. Therefore, these data are consistent with the hypothesis that mitochondrial dysfunction may be a consequence rather than cause of muscular fat accumulation, and that it develops when the protective mechanisms can—on the longer term—no longer cope with high levels of muscular fatty acids, and as a consequence lipotoxicity occurs. It should be noted however that such lipid-induced mitochondrial dysfunction may lead to progressive deterioration of muscular oxidative capacity and accumulation of lipid intermediates in skeletal muscle, therefore not excluding that mitochondrial dysfunction in fact does play a role in the etiology of type 2 diabetes mellitus. Unfortunately, so far human studies that manipulated muscular fat content and examined the effect on mitochondrial function are lacking.

5. How can fatty acids lead to mitochondrial dysfunction in muscle?

Next to the production of ATP, mitochondria are also the major source of reactive oxygen species (ROS). Mitochondrial ROS can rapidly react with mtDNA, protein and lipids, thereby leading to

oxidative damage. In muscle cells fatty acids accumulate in the vicinity of mitochondria and these fatty acids are very prone to ROS-induced oxidative damage, resulting in the formation of lipid peroxides. Especially accumulation of fatty acids in the inner mitochondrial membrane of mitochondria, at the site where ROS are formed, would be susceptible to peroxidation, subsequently inducing oxidative damage to the mitochondrial machinery. To prevent mitochondrial accumulation of fatty acids, their entry into mitochondria is regulated by the enzyme CPT1 that serves as an inward transporter of oxidizable fatty acids. However, this system cannot completely prevent the diffusion of non-metabolizable fatty acid into the mitochondria. Mitochondrial membranes consist of lipid bilayers and therefore fatty acids can still 'enter' the mitochondria matrix membrane via a so-called 'flip-flop' mechanism over the membrane [45]. However, these fatty acids cannot be oxidized due to the lack of acyl-CoA synthetase inside the matrix and likely are incorporated in the inner mitochondrial membrane, where they would be vulnerable to oxidative damage. This 'passive diffusion' is more likely to occur under conditions of high fatty acid availability and low demand, as is often the case in the pre-diabetic and diabetic state. This notion is supported by the observation that skeletal muscle of obese insulin resistant subjects not only contains a higher amount of intramyocellular lipid, but these lipids also showed a higher degree of lipid peroxidation [46]. It is tempting to suggest that these lipid peroxides lead to oxidative damage to mitochondrial structures and contribute to the reduced mitochondrial capacity observed in (pre-)diabetic patients [9]. Furthermore, this suggestion is also in accordance with the finding of Bonnard et al. [42] showing that high-fat diet induced mitochondrial dysfunction was associated with increased ROS production.

Mitochondrial ROS production depends highly on the proton gradient over the inner mitochondrial membrane (which drives ATP synthesis) and a high proton gradient will increase ROS production. One way to lower the proton gradient is by so-called mitochondrial uncoupling, a process in which a reduction of the proton gradient is not coupled to ATP production, but is due to proton leakage. Since the relationship between ROS production and the proton gradient is exponential, already a small decrease in membrane potential ("mild uncoupling") will reduce mitochondrial ROS production considerably [47]. Therefore, at the expense of a slight inefficiency in ATP production, mitochondrial uncoupling is a powerful tool to control ROS formation and hence to preserve mitochondrial functioning. Recently, this mitochondrial uncoupling was linked to the maintenance of mitochondrial function in human skeletal muscle during aging [48]. Thus, it has been observed that during aging mitochondrial function decreased in the well-coupled dorsal interosseus muscle while mitochondrial function was maintained in mildly uncoupled mitochondria from aging tibialis anterior muscle [48]. Although associative, these novel data suggest that mitochondrial uncoupling might protect against (age-induced) mitochondrial dysfunction.

As outlined above, especially fatty acids in the vicinity of mitochondria would be prone to oxidative damage, leading to the formation of lipid-peroxides. Interestingly, it is known for a long time that fatty acids are capable of mitochondrial uncoupling [49], but the reason why fatty acids do so is less clear. It can be hypothesized that fatty-acid induced uncoupling lowers mitochondrial ROS production and thereby prevents mitochondrial lipotoxicity. Although, so far no direct evidence for this hypothesis has been provided, we [50,51] and others [52,53] have previously suggested that the muscle specific mitochondrial uncoupling protein-3 (UCP3) may be involved in the protection of mitochondria against lipid-induced mitochondrial damage. UCP3 may do so by exporting non-metabolizable fatty acid anions or peroxides away from the mitochondrial inner membrane before they are attacked by ROS, or by directly lowering ROS production via mild mitochondrial uncoupling. We have recently shown that mitochondrial ROS




Fig. 2. Mitochondrial uncoupling as a proposed protective mechanisms against mitochondrial lipotoxicity: mitochondria produce reactive oxygen species (ROS) that can attack mitochondrial fatty acids, leading to lipid peroxides. These peroxides are highly reactive and could lead to damage to the mitochondrial machinery. However, fatty acids can activate processes leading to mitochondrial uncoupling, thereby reducing the proton gradient over the inner mitochondrial membrane. A lowering of the proton gradient leads to a reduction of ROS production, providing a feedback mechanism limiting mitochondrial lipotoxicity.

production, measured in a direct way by electron spin resonance of isolated mitochondria, increased with age in wild type mice, but this age-induced increase in mitochondrial ROS production was blunted in mice overexpressing UCP3 [54]. In addition, we have shown that the ablation of UCP3 was accompanied by higher levels of muscular lipid peroxidation [55]. We have shown that UCP3 is specifically upregulated in skeletal muscle when a dysbalance between fatty acid delivery and fatty acid oxidative capacity exists in muscle (for an extensive review, see: [51]). In short, UCP3 is upregulated with high-fat diets [56,57], fasting [58], etomoxir treatment (which inhibits the mitochondrial fatty acid oxidation) [28,59] and lipid infusion [33], all conditions that are associated by excessive lipid accumulation in skeletal muscle. On the other hand, interventions improving fat oxidative capacity, like endurance training [60,61] and weight loss [62], or lowering circulatory fatty acids [63,64] are associated with a decrease in UCP3. Interestingly, UCPs are activated by fatty acids and/or by peroxidation products of fatty acids [53], and when activated UCPs may reduce mitochondrial ROS production [53,54]. Therefore, it can be suggested that UCP3 is involved in the protection against mitochondrial lipotoxicity by lowering ROS production when activated by fatty acids (Fig. 2). In that respect, it is of interest to note that only type 2 diabetic patients and pre-diabetic subjects, who as outlined above are characterized by excessive fat accumulation in skeletal muscle and by mitochondrial dysfunction, have ~50% lower UCP3 protein levels [65,66] compared to obese control subjects who have similar IMCL content but normal mitochondrial function. This suggests that fat accumulation in skeletal muscle, combined with a defective protection mechanisms and probably elevated ROS levels, may lead to mitochondrial dysfunction.

6. Concluding remarks

In summary, although the evidence for mitochondrial dysfunction in type 2 diabetes mellitus is ample, there is so far no evidence that this reduced mitochondrial function is causal in the development of the disease. If anything, the results obtained so far tell us that the relation between mitochondrial function and the development of type 2 diabetes mellitus is not as simple as originally assumed. The initial suggestion that a reduced mitochondrial function precedes the accumulation of IMCL and insulin resistance

is not supported by all studies, as several studies show no differences in IMCL despite reductions in mitochondrial function in insulin-resistant and/or diabetic subjects [17,20]. Therefore, it cannot be excluded that a reduced mitochondrial function may in fact be the consequence rather than cause of the diabetic state, for example caused by lipotoxic mechanisms [50]. The findings that plasma fatty acid levels reduce the expression of PGC1 α [33,34] are negatively related to fasting muscular ATP synthesis [17], and impair insulin-stimulated ATP synthesis [67], as well as the observation of increased mitochondrial damage in type 2 diabetic patients [9] support this hypothesis. Whether mitochondrial dysfunction in type 2 diabetic patients and insulin-resistant subjects is due to reduced protective mechanisms against mitochondrial lipotoxicity deserves further study.

Acknowledgments

Dr. P.Schrauwen is supported by a VICI Research Grant for innovative research from the Netherlands Organization for Scientific Research (Grant 918.96.618). Dr. M. Hesselink is supported by a VIDI Research Grant for innovative research from the Netherlands Organization for Scientific Research (grant 917.66.359).

References

- [1] S. Wild, G. Roglic, A. Green, R. Sicree, H. King, Global prevalence of diabetes: estimates for the year 2000 and projections for 2030, *Diabetes Care* 27 (2004) 1047–1053.
- [2] J.D. McGarry, Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes, *Diabetes* 51 (2002) 7–18.
- [3] B.H. Goodpaster, J. He, S. Watkins, D.E. Kelley, Skeletal muscle lipid content and insulin resistance: evidence for a paradox in endurance-trained athletes, *J. Clin. Endocrinol. Metab.* 86 (2001) 5755–5761.
- [4] G. Perseghin, P. Scifo, F. De Cobelli, E. Pagliato, A. Battezzati, C. Arcelloni, A. Vanzulli, G. Testolin, G. Pozza, A. Del Maschio, L. Luzi, Intramyocellular triglyceride content is a determinant of *in vivo* insulin resistance in humans: a 1H-13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents, *Diabetes* 48 (1999) 1600–1606.
- [5] S. Jacob, J. Machann, K. Rett, K. Brechtel, A. Volk, W. Renn, E. Maerker, S. Matthaei, F. Schick, C.D. Claussen, H.U. Haring, Association of increased intramyocellular lipid content with insulin resistance in lean nondiabetic offspring of type 2 diabetic subjects, *Diabetes* 48 (1999) 1113–1119.
- [6] V.B. Schrauwen-Hinderling, M.K. Hesselink, P. Schrauwen, M.E. Kooi, Intramyocellular lipid content in human skeletal muscle, *Obesity (Silver Spring)* 14 (2006) 357–367.
- [7] D.E. Kelley, L.J. Mandarino, Fuel selection in human skeletal muscle in insulin resistance: a reexamination, *Diabetes* 49 (2000) 677–683.
- [8] G.I. Shulman, Cellular mechanisms of insulin resistance, *J. Clin. Invest.* 106 (2000) 171–176.
- [9] D.E. Kelley, J. He, E.V. Menshikova, V.B. Ritov, Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes, *Diabetes* 51 (2002) 2944–2950.
- [10] M.E. Patti, A.J. Butte, S. Crunkhorn, K. Cusi, R. Berria, S. Kashyap, Y. Miyazaki, I. Kohane, M. Costello, R. Saccone, E.J. Landaker, A.B. Goldfine, E. Mun, R. DeFronzo, J. Finlayson, C.R. Kahn, L.J. Mandarino, Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1, *Proc. Natl. Acad. Sci. U. S. A.* 100 (2003) 8466–8471.
- [11] V.K. Mootha, C.M. Lindgren, K.F. Eriksson, A. Subramanian, S. Sihag, J. Lehar, P. Puigserver, E. Carlsson, M. Ridderstrale, E. Laurila, N. Houstis, M.J. Daly, N. Patterson, J.P. Mesirov, T.R. Golub, P. Tamayo, B. Spiegelman, E.S. Lander, J.N. Hirschhorn, D. Altshuler, L.C. Groop, PGC-1 α -responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes, *Nat. Genet.* 34 (2003) 267–273.
- [12] M. Mensink, M.K. Hesselink, A.P. Russell, G. Schaart, J.P. Sels, P. Schrauwen, Improved skeletal muscle oxidative enzyme activity and restoration of PGC-1 α and PPAR β /delta gene expression upon rosiglitazone treatment in obese patients with type 2 diabetes mellitus, *Int. J. Obes. (Lond)* (2007).
- [13] L.K. Heilbronn, S.K. Gan, N. Turner, L.V. Campbell, D.J. Chisholm, Markers of mitochondrial biogenesis and metabolism are lower in overweight and obese insulin-resistant subjects, *J. Clin. Endocrinol. Metab.* 92 (2007) 1467–1473.
- [14] M. Fan, J. Rhee, J. St-Pierre, C. Handschin, P. Puigserver, J. Lin, S. Jaeger, H. Erdjument-Bromage, P. Tempst, B.M. Spiegelman, Suppression of mitochondrial respiration through recruitment of p160 myb binding protein to PGC-1 α : modulation by p38 MAPK, *Genes Dev.* 18 (2004) 278–289.
- [15] K.F. Petersen, D. Befroy, S. Dufour, J. Dziura, C. Ariyan, D.L. Rothman, L. DiPietro, G.W. Cline, G.I. Shulman, Mitochondrial dysfunction in the elderly: possible role in insulin resistance, *Science* 300 (2003) 1140–1142.
- [16] K.F. Petersen, S. Dufour, D. Befroy, R. Garcia, G.I. Shulman, Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes, *N. Engl. J. Med.* 350 (2004) 664–671.

- [17] J. Szendroedi, A.I. Schmid, M. Chmelik, C. Toth, A. Brehm, M. Krssak, P. Nowotny, M. Wolzt, W. Waldhausl, M. Roden, Muscle mitochondrial ATP synthesis and glucose transport/phosphorylation in Type 2 diabetes, *PLoS Med.* 4 (2007) e154.
- [18] R.A. Meyer, A linear model of muscle respiration explains monoexponential phosphocreatine changes, *Am. J. Physiol.* 254 (1988) C548–553.
- [19] G.J. Kemp, G.K. Radda, Quantitative interpretation of bioenergetic data from ³¹P and ¹H magnetic resonance spectroscopic studies of skeletal muscle: an analytical review, *Magn. Reson. Q.* 10 (1994) 43–63.
- [20] V.B. Schrauwen-Hinderling, M.E. Kooi, M.K. Hesselink, J.A. Jeneson, W.H. Backes, C.J. van Echteld, J.M. van Engelshoven, M. Mensink, P. Schrauwen, Impaired *in vivo* mitochondrial function but similar intramyocellular lipid content in patients with type 2 diabetes mellitus and BMI-matched control subjects, *Diabetologia* 50 (2007) 113–120.
- [21] E. Phielix, V.B. Schrauwen-Hinderling, M. Mensink, E. Lenaers, R. Meex, J. Hoeks, M.E. Kooi, E. Moonen-Kornips, J.P. Sels, M.K. Hesselink, P. Schrauwen, Lower intrinsic ADP-stimulated mitochondrial respiration underlies *in vivo* mitochondrial dysfunction in muscle of male type 2 diabetic patients, *Diabetes* 57 (2008) 2943–2949.
- [22] R. Boushel, E. Gnaiger, P. Schjerling, M. Skovbro, R. Kraunsøe, F. Dela, Patients with type 2 diabetes have normal mitochondrial function in skeletal muscle, *Diabetologia* 50 (2007) 790–796.
- [23] M. Mogensen, K. Sahlin, M. Fernstrom, D. Glinborg, B.F. Vind, H. Beck-Nielsen, K. Hojlund, Mitochondrial respiration is decreased in skeletal muscle of patients with type 2 diabetes, *Diabetes* 56 (2007) 1529–1529.
- [24] J.A. Pospisilik, C. Knauf, N. Joza, P. Benit, M. Orthofer, P.D. Cani, I. Ebersberger, T. Nakashima, R. Sarao, G. Neely, H. Esterbauer, A. Kozlov, C.R. Kahn, G. Kroemer, P. Rustin, R. Burcelin, J.M. Penninger, Targeted deletion of AIF decreases mitochondrial oxidative phosphorylation and protects from obesity and diabetes, *Cell* 131 (2007) 476–491.
- [25] A. Wredenberg, C. Frey, M.E. Sandstrom, A. Katz, R. Wibom, H. Westerblad, N.G. Larsson, Respiratory chain dysfunction in skeletal muscle does not cause insulin resistance, *Biochem. Biophys. Res. Commun.* 350 (2006) 202–207.
- [26] B.N. Finck, C. Bernal-Mizrachi, D.H. Han, T. Coleman, N. Sambandam, L.L. LaRiviere, J.O. Holloszy, C.F. Semenkovich, D.P. Kelly, A potential link between muscle peroxisome proliferator-activated receptor- α signaling and obesity-related diabetes, *Cell Metab.* 1 (2005) 133–144.
- [27] P.J. Randle, P.B. Garland, C.N. Hales, E.A. Newsholme, The glucose-fatty acid cycle: Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus, *Lancet* i (1963) 785–789.
- [28] P. Schrauwen, V. Hinderling, M.K.C. Hesselink, G. Schaart, E. Kornips, W.H.M. Saris, M. Westerterp-Plantega, W. Langhans, Etomoxir-induced increase in UCP3 supports a role of uncoupling protein 3 as a mitochondrial fatty acid anion exporter, *FASEB J.* 16 (12) (2002) 1688–1690. 10.1096/fj.1002-0275fje.
- [29] G. Boden, B. Lebed, M. Schatz, C. Homko, S. Lemieux, Effects of acute changes of plasma free fatty acids on intramyocellular fat content and insulin resistance in healthy subjects, *Diabetes* 50 (2001) 1612–1617.
- [30] V.B. Schrauwen-Hinderling, M.E. Kooi, M.K. Hesselink, E. Moonen-Kornips, G. Schaart, K.J. Mustard, D.G. Hardie, W.H. Saris, K. Nicolay, P. Schrauwen, Intramyocellular lipid content and molecular adaptations in response to a 1-week high-fat diet, *Obes. Res.* 13 (2005) 2088–2094.
- [31] P. Schrauwen, W.D. van Marken Lichtenbelt, W.H. Saris, K.R. Westerterp, Changes in fat oxidation in response to a high-fat diet, *Am. J. Clin. Nutr.* 66 (1997) 276–282.
- [32] J.O. Holloszy, Skeletal muscle “mitochondrial deficiency” does not mediate insulin resistance, *Am. J. Clin. Nutr.* 89 (2009) 463S–466S.
- [33] J. Hoeks, M.K. Hesselink, A.P. Russell, M. Mensink, W.H. Saris, R.P. Mensink, P. Schrauwen, Peroxisome proliferator-activated receptor- γ coactivator-1 and insulin resistance: acute effect of fatty acids, *Diabetologia* 49 (2006) 2419–2426.
- [34] D.K. Richardson, S. Kashyap, M. Bajaj, K. Cusi, S.J. Mandarino, J. Finlayson, R.A. DeFronzo, C.P. Jenkinson, L.J. Mandarino, Lipid infusion decreases the expression of nuclear encoded mitochondrial genes and increases the expression of extracellular matrix genes in human skeletal muscle, *J. Biol. Chem.* 280 (2005) 10290–10297.
- [35] L.M. Sparks, H. Xie, R.A. Koza, R. Mynatt, M.W. Hulver, G.A. Bray, S.R. Smith, A high-fat diet coordinately downregulates genes required for mitochondrial oxidative phosphorylation in skeletal muscle, *Diabetes* 54 (2005) 1926–1933.
- [36] N. Turner, C.R. Bruce, S.M. Beale, K.L. Hoehn, T. So, M.S. Rolph, G.J. Cooney, Excess lipid availability increases mitochondrial fatty acid oxidative capacity in muscle: evidence against a role for reduced fatty acid oxidation in lipid-induced insulin resistance in rodents, *Diabetes* 56 (2007) 2085–2092.
- [37] J. Hoeks, J.J. Briede, J. de Vogel, G. Schaart, M. Nabben, E. Moonen-Kornips, M.K. Hesselink, P. Schrauwen, Mitochondrial function, content and ROS production in rat skeletal muscle: effect of high-fat feeding, *FEBS Lett.* 582 (2008) 510–516.
- [38] C.R. Hancock, D.H. Han, M. Chen, S. Terada, T. Yasuda, D.C. Wright, J.O. Holloszy, High-fat diets cause insulin resistance despite an increase in muscle mitochondria, *Proc. Natl. Acad. Sci. U. S. A.* 105 (2008) 7815–7820.
- [39] E. Chanseume, A.L. Tardy, J. Salles, C. Giraudet, P. Rousset, A. Tissandier, Y. Boirie, B. Morio, Chronological approach of diet-induced alterations in muscle mitochondrial functions in rats, *Obesity (Silver Spring)* 15 (2007) 50–59.
- [40] D. Laurent, B. Yerby, R. Deacon, J. Gao, Diet-induced modulation of mitochondrial activity in rat muscle, *Am. J. Physiol. Endocrinol. Metab.* 293 (2007) E1169–1177.
- [41] H.M. De Feyter, N.M. van den Broek, S.F. Praet, K. Nicolay, L.J. van Loon, J.J. Prompers, Early or advanced stage type 2 diabetes is not accompanied by *in vivo* skeletal muscle mitochondrial dysfunction, *Eur. J. Endocrinol.* 158 (2008) 643–653.
- [42] C. Bonnard, A. Durand, S. Peyrol, E. Chanseume, M.A. Chauvin, B. Morio, H. Vidal, J. Rieusset, Mitochondrial dysfunction results from oxidative stress in the skeletal muscle of diet-induced insulin-resistant mice, *J. Clin. Invest.* 118 (2008) 789–800.
- [43] E.J. Anderson, M.E. Lustig, K.E. Boyle, T.L. Woodlief, D.A. Kane, C.T. Lin, J.W. Price, L. 3rd, P.S. Kang, H.H. Rabinovitch, J.A. Szeto, R.N. Houmar, D.H. Cortright, P.D. Wasserman, Neuffer, P.D., Mitochondrial H₂O₂ emission and cellular redox state link excess fat intake to insulin resistance in both rodents and humans, *J. Clin. Invest.* 119 (3) (2009) 573–581.
- [44] N. Houstis, E.D. Rosen, E.S. Lander, Reactive oxygen species have a causal role in multiple forms of insulin resistance, *Nature* 440 (2006) 944–948.
- [45] J.K. Ho, R.I. Duclos Jr., J.A. Hamilton, Interactions of acyl carnitines with model membranes: a (¹³C)-NMR study, *J. Lipid Res.* 43 (2002) 1429–1439.
- [46] A.P. Russell, G. Gastaldi, E. Bobbioni-Harsch, P. Arboit, C. Gobelet, O. Deriaz, A. Golay, J.L. Witztum, J.P. Giacobino, Lipid peroxidation in skeletal muscle of obese as compared to endurance-trained humans: a case of good vs. bad lipids? *FEBS Lett.* 551 (2003) 104–106.
- [47] S.S. Korshunov, V.P. Skulachev, A.A. Starkov, High protonic potential actuates a mechanism of production of reactive oxygen species in mitochondria, *FEBS Lett.* 416 (1997) 15–18.
- [48] C.E. Amara, E.G. Shankland, S.A. Jubrias, D.J. Marcinek, M.J. Kushmerick, K.E. Conley, Mild mitochondrial uncoupling impacts cellular aging in human muscles *in vivo*, *Proc. Natl. Acad. Sci. U. S. A.* 104 (2007) 1057–1062.
- [49] P. Borst, J.A. Loos, E.J. Christ, E.C. Slater, Uncoupling activity of long-chain fatty acids, *Biochim. Biophys. Acta* 62 (1962) 509–518.
- [50] P. Schrauwen, M.K. Hesselink, Oxidative capacity, lipotoxicity, and mitochondrial damage in type 2 diabetes, *Diabetes* 53 (2004) 1412–1417.
- [51] P. Schrauwen, J. Hoeks, M.K. Hesselink, Putative function and physiological relevance of the mitochondrial uncoupling protein-3: involvement in fatty acid metabolism? *Prog. Lipid Res.* 45 (2006) 17–41.
- [52] F. Goglia, V.P. Skulachev, A function for novel uncoupling proteins: antioxidant defense of mitochondrial matrix by translocating fatty acid peroxides from the inner to the outer membrane leaflet, *FASEB J.* 17 (2003) 1585–1591.
- [53] K.S. Echta, T.C. Esteves, J.L. Pakay, M.B. Jakabsons, A.J. Lambert, M. Portero-Otin, R. Pamplona, A.J. Vidal-Puig, S. Wang, S.J. Roebuck, M.D. Brand, A signalling role for 4-hydroxy-2-nonenal in regulation of mitochondrial uncoupling, *EMBO J.* 22 (2003) 4103–4110.
- [54] M. Nabben, J. Hoeks, J.J. Briede, J.F. Glatz, E. Moonen-Kornips, M.K. Hesselink, P. Schrauwen, The effect of UCP3 overexpression on mitochondrial ROS production in skeletal muscle of young versus aged mice, *FEBS Lett.* 582 (2008) 4147–4152.
- [55] J. Hoeks, M.K. Hesselink, W. Sluiter, G. Schaart, J. Willems, A. Morrisson, J.C. Clapham, W.H. Saris, P. Schrauwen, The effect of high-fat feeding on intramuscular lipid and lipid peroxidation levels in UCP3-ablated mice, *FEBS Lett.* 580 (2006) 1371–1375.
- [56] M.K.C. Hesselink, P.L. Greenhaff, D. Constantin-Teodosiu, E. Hultman, W.H.M. Saris, R. Nieuwlaet, G. Schaart, E. Kornips, P. Schrauwen, Increased uncoupling protein 3 content does not affect mitochondrial function in human skeletal muscle *in vivo*, *J. Clin. Invest.* 111 (2003) 479–486.
- [57] D.S. Weigle, L.E. Selfridge, M.W. Schwartz, R.J. Seeley, D.E. Cummings, P.J. Havel, J.L. Kuijper, H. BertrandelRio, Elevated free fatty acids induce uncoupling protein 3 expression in muscle. A potential explanation for the effect of fasting, *Diabetes* 47 (1998) 298–302.
- [58] L. Millet, H. Vidal, F. Andreelli, D. Larrouy, J.-P. Riou, D. Ricquier, M. Laville, D. Langin, Increased uncoupling protein-2 and -3 mRNA expression during fasting in obese and lean humans, *J. Clin. Invest.* 100 (1997) 2665–2670.
- [59] S. Samec, J. Seydoux, A.G. Dulloo, Role of UCP homologues in skeletal muscles and brown adipose tissue: mediators of thermogenesis or regulators of lipids as fuel substrate? *FASEB J.* 12 (1998) 715–724.
- [60] A.P. Russell, E. Som, M. Praz, A. Crettenand, O. Hartley, A. Melotti, J.P. Giacobino, P. Muzzin, C. Gobelet, O. Deriaz, UCP3 protein regulation in human skeletal muscle fibre types I, IIa and IIx is dependent on exercise intensity, *J. Physiol.* 550 (2003) 855–861.
- [61] P. Schrauwen, F.J. Troost, J. Xia, E. Ravussin, W.H. Saris, Skeletal muscle UCP2 and UCP3 expression in trained and untrained male subjects, *Int. J. Obes. Relat. Metab. Disord.* 23 (1999) 966–972.
- [62] G. Mingrone, G. Rosa, A.V. Greco, M. Manco, N. Vega, M.K. Hesselink, M. Castagneto, P. Schrauwen, H. Vidal, Decreased uncoupling protein expression and intramyocytic triglyceride depletion in formerly obese subjects, *Obes. Res.* 11 (2003) 632–640.
- [63] J. Hoeks, M.A. van Baak, M.K. Hesselink, G.B. Hul, H. Vidal, W.H. Saris, P. Schrauwen, Effect of beta1- and beta2-adrenergic stimulation on energy expenditure, substrate oxidation, and UCP3 expression in humans, *Am. J. Physiol. Endocrinol. Metab.* 285 (2003) E775–782.
- [64] S. Samec, J. Seydoux, A.G. Dulloo, Interorgan signaling between adipose tissue metabolism and skeletal muscle uncoupling protein homologs: is there a role for circulating free fatty acids? *Diabetes* 47 (1998) 1693–1698.
- [65] P. Schrauwen, M.K. Hesselink, E.E. Blaak, L.B. Borghouts, G. Schaart, W.H. Saris, H.A. Keizer, Uncoupling protein 3 content is decreased in skeletal muscle of patients with type 2 diabetes, *Diabetes* 50 (2001) 2870–2873.
- [66] P. Schrauwen, M. Mensink, G. Schaart, E. Moonen-Kornips, J.P. Sels, E.E. Blaak, A.P. Russell, M.K. Hesselink, Reduced skeletal muscle uncoupling protein-3 content in prediabetic subjects and type 2 diabetic patients: restoration by rosiglitazone treatment, *J. Clin. Endocrinol. Metab.* 91 (2006) 1520–1525.
- [67] A. Brehm, M. Krssak, A.I. Schmid, P. Nowotny, W. Waldhausl, M. Roden, Increased lipid availability impairs insulin-stimulated ATP synthesis in human skeletal muscle, *Diabetes* 55 (2006) 136–140.